Mesna side effects which imitate vasculitis

E. Reinhold-Keller; J. Mohr; E. Christophers; K. Nordmann; W. L. Gross

doi:10.1007/BF00180290

Mesna side effects which imitate vasculitis

E. Reinhold-Keller^*, J. Mohr, E. Christophers, K. Nordmann, W. L. Gross

^*Corresponding author for this work

Clinic of Rheumatology

University of Kiel

18 Citations (Scopus)

Abstract

Mesna (sodium-2-mercaptoethansulfonate) is used in the prophylaxis of cyclophosphamide (CYC)-induced hemorrhagic cystitis. Four patients being treated with "low dose" CYC and prednisone for vasculitis developed severe side effects to Mesna. Fever, arthralgia, myalgia, tachycardia, electrocardiogram changes consistent with perimyocarditis, erythroderma, bullous skin and mucous membrane lesions, and abdominal complaints with profuse diarrhea were noted approximately 3 weeks after the initiation of therapy for CYC-induced leukopenia and a conservatively reduced prednisone dosage. Positive reexposure tests confirmed the association to Mesna use, and hypersensitivity skin tests demonstrated a delayed hypersensitivity reaction.

Original language	English
Journal	The Clinical Investigator
Volume	70
Issue number	8
Pages (from-to)	698-704
Number of pages	7
ISSN	0941-0198
DOIs	https://doi.org/10.1007/BF00180290
Publication status	Published - 08.1992

Research Areas and Centers

Academic Focus: Center for Infection and Inflammation Research (ZIEL)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/BF00180290

Cite this

@article{fa19575f4f1144539a5205ba0ac008a1,

title = "Mesna side effects which imitate vasculitis",

abstract = "Mesna (sodium-2-mercaptoethansulfonate) is used in the prophylaxis of cyclophosphamide (CYC)-induced hemorrhagic cystitis. Four patients being treated with {"}low dose{"} CYC and prednisone for vasculitis developed severe side effects to Mesna. Fever, arthralgia, myalgia, tachycardia, electrocardiogram changes consistent with perimyocarditis, erythroderma, bullous skin and mucous membrane lesions, and abdominal complaints with profuse diarrhea were noted approximately 3 weeks after the initiation of therapy for CYC-induced leukopenia and a conservatively reduced prednisone dosage. Positive reexposure tests confirmed the association to Mesna use, and hypersensitivity skin tests demonstrated a delayed hypersensitivity reaction.",

author = "E. Reinhold-Keller and J. Mohr and E. Christophers and K. Nordmann and Gross, {W. L.}",

year = "1992",

month = aug,

doi = "10.1007/BF00180290",

language = "English",

volume = "70",

pages = "698--704",

journal = "The Clinical Investigator",

issn = "0941-0198",

number = "8",

}

TY - JOUR

T1 - Mesna side effects which imitate vasculitis

AU - Reinhold-Keller, E.

AU - Mohr, J.

AU - Christophers, E.

AU - Nordmann, K.

AU - Gross, W. L.

PY - 1992/8

Y1 - 1992/8

N2 - Mesna (sodium-2-mercaptoethansulfonate) is used in the prophylaxis of cyclophosphamide (CYC)-induced hemorrhagic cystitis. Four patients being treated with "low dose" CYC and prednisone for vasculitis developed severe side effects to Mesna. Fever, arthralgia, myalgia, tachycardia, electrocardiogram changes consistent with perimyocarditis, erythroderma, bullous skin and mucous membrane lesions, and abdominal complaints with profuse diarrhea were noted approximately 3 weeks after the initiation of therapy for CYC-induced leukopenia and a conservatively reduced prednisone dosage. Positive reexposure tests confirmed the association to Mesna use, and hypersensitivity skin tests demonstrated a delayed hypersensitivity reaction.

AB - Mesna (sodium-2-mercaptoethansulfonate) is used in the prophylaxis of cyclophosphamide (CYC)-induced hemorrhagic cystitis. Four patients being treated with "low dose" CYC and prednisone for vasculitis developed severe side effects to Mesna. Fever, arthralgia, myalgia, tachycardia, electrocardiogram changes consistent with perimyocarditis, erythroderma, bullous skin and mucous membrane lesions, and abdominal complaints with profuse diarrhea were noted approximately 3 weeks after the initiation of therapy for CYC-induced leukopenia and a conservatively reduced prednisone dosage. Positive reexposure tests confirmed the association to Mesna use, and hypersensitivity skin tests demonstrated a delayed hypersensitivity reaction.

UR - http://www.scopus.com/inward/record.url?scp=0026666658&partnerID=8YFLogxK

U2 - 10.1007/BF00180290

DO - 10.1007/BF00180290

M3 - Journal articles

C2 - 1392448

AN - SCOPUS:0026666658

SN - 0941-0198

VL - 70

SP - 698

EP - 704

JO - The Clinical Investigator

JF - The Clinical Investigator

IS - 8

ER -

Mesna side effects which imitate vasculitis

Abstract

Research Areas and Centers

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this